Skip to main content

Philip Hughes

Research Scientist, Senior
Pharmacology & Cancer Biology
Research Dr, LSRC Rm C115, Pharmacology and Cancer Biology, Durham, NC 27710

Selected Grants


Development of Diagnostic/Therapeutic Agents Targeting Borrelia burgdorferi HtpG

ResearchSenior Research Scientist · Awarded by Department of Defense · 2024 - 2027

Development of an oral targeted drug for treatment of bartonelloses

ResearchSenior Research Scientist · Awarded by Steven & Alexandra Cohen Foundation · 2021 - 2025

Preclinical Development Of Novel Borrelia Sp. Targeting Therapeutic And Diagnostic Imaging Agents.

ResearchSenior Research Scientist · Awarded by Bay Area Lyme Foundation · 2021 - 2025

Improving the Oral Bioavailability and In vivo Efficacy of the TAK 1 Inhibitor, Takinib.

ResearchResearch Scientist · Awarded by Eydis Bio Inc. · 2019 - 2021

An orally bioavailable broad-spectrum Hsp90 inhibitor (Hsp90i) therapy to suppress emerging Coronavirus (CoV) infections

ResearchResearch Scientist · Awarded by Good Ventures Foundation · 2020 - 2021

External Relationships


  • Eydis Bio, Inc.
  • Innovasyn, LLC

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.